GU Cancers 2026 | Kidney cancer highlights at ASCO GU 2026: LITESPARK-011 & LITESPARK-022

Several phase three trials that have read out here in kidney cancer at GU ASCO. We saw LITESPARK-011 trial with lenvatinib and belzutifan compared to Cabozantinib. This is the first trial that has shown a progression-free survival benefit, that statistically and clinically significant benefit of the combination over cabozantinib. And so I do think this represents a way for us to understand sequencing approaches, for us to use lenvatinib and belzutifan in the refractory setting. Personally, I think we should probably be thinking about using cabozantinib sooner so that we can actually switch out those mechanisms in the later line forlenvatinib and belzutifan. In addition, the second large phase three trial that read out here at GUASCO was LITESPARK-022. And this is a trial in the adjuvant setting for clear cell kidney cancer where patients post-nephrectomy are randomized to pembrolizumab and belzutifanversus pembrolizumab and placebo. It was a really large trial, over 1,800 patients, but they did show a disease-free survival benefit. Now, the overall survival is still not mature, but I do think in some patients who are considering adjuvant treatments that we are starting to think about a combination approach. This would be our first combination in the adjuvant setting.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.